Journal of Neurology

, Volume 256, Issue 3, pp 436–442 | Cite as

“Vestibular migraine”: effects of prophylactic therapy with various drugs

A retrospective study


Vertigo is frequently associated with migraine, and sometimes it is the cardinal symptom. This type of migraine is called “vestibular migraine”, “migrainous vertigo”, or “migraine-associated vertigo”. Earlier findings on effective prophylactic medication for such migraine attacks and their clinical features are few and insufficient. Our aim was to study the influence of prophylactic therapy on this type of migraine and to specify its clinical features. In a retrospective approach 100 patients (median age 47 years, range 21–72 years) with definite or probable vestibular migraine [1] were divided into two groups: those with (74 patients) and those without drug prophylaxis (26 patients). They were then interviewed by telephone at least 6 months after beginning therapy. All patients receiving medical prophylaxis showed a decrease of duration, intensity, and frequency of episodic vertigo as well as nearly all its associated features (p < 0.01). The group without medical prophylactic therapy showed only a reduction of vertigo intensity. Only 39 % of the 100 patients met the current IHS criteria for a basilartype migraine [2]. Thus, we propose that a new category – “vestibular migraine” – should be added to the HIS criteria. Furthermore, our data show that prophylactic medication may be effective for treating vestibular migraine and its associated symptoms; therefore, patient’s response to medical therapy may provide guidance in the diagnostic process of vestibular migraine.

Key words

vestibular migraine vertigo prophylactic therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56:436–441PubMedGoogle Scholar
  2. 2.
    2. International Classification of Headache Disorders, 2nd edition (2004) Cephalalgia 24:9–160Google Scholar
  3. 3.
    Dieterich M, Brandt T (1999) Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 246:883–892PubMedCrossRefGoogle Scholar
  4. 4.
    Brandt T (2004) A chameleon among the episodic vertigo syndromes: ‘migrainous vertigo’ or ‘vestibular migraine’. Cephalalgia 24:81–82PubMedCrossRefGoogle Scholar
  5. 5.
    Brandt T, Strupp M (2006) Migraine and vertigo: classification, clinical features, and special treatment considerations. Headache Currents 3:12–19CrossRefGoogle Scholar
  6. 6.
    Neuhauser H, Lempert T (2004) Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 24:83–91PubMedCrossRefGoogle Scholar
  7. 7.
    Brantberg K, Trees N, Baloh RW (2005) Migraine-associated vertigo. Acta Otolaryngol 125:276–279PubMedCrossRefGoogle Scholar
  8. 8.
    Stahl JS, Daroff RB (2001) Time for more attention to migrainous vertigo? Neurology 56:428–429PubMedGoogle Scholar
  9. 9.
    Bikhazi P, Jackson C, Ruckenstein MJ (1997) Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 18:350–354PubMedGoogle Scholar
  10. 10.
    Johnson GD (1998) Medical management of migraine-related dizziness and vertigo. Laryngoscope 108:1–28PubMedCrossRefGoogle Scholar
  11. 11.
    Reploeg MD, Goebel JA (2002) Migraine- associated dizziness: patient characteristics and management options. Otol Neurotol 23:364–371PubMedCrossRefGoogle Scholar
  12. 12.
    Bisdorff AR (2004) Treatment of migraine related vertigo with lamotrigine: an observational study. Bull Soc Sci Med Grand Duche Luxemb 2:103–108PubMedGoogle Scholar
  13. 13.
    Carmona S, Settecase N (2005) Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. Ann N Y Acad Sci 1039:517–520PubMedCrossRefGoogle Scholar
  14. 14.
    Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T, Lempert T (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67:1028–1033PubMedCrossRefGoogle Scholar
  15. 15.
    Bank J, Marton S (2000) Hungarian migraine epidemiology. Headache 40:164–169PubMedCrossRefGoogle Scholar
  16. 16.
    Ulrich V, Olesen J, Gervil M, Russell MB (2000) Possible risk factors and precipitants for migraine with aura in discordant twin-pairs: a populationbased study. Cephalalgia 20:821–825PubMedCrossRefGoogle Scholar
  17. 17.
    Kayan A, Hood JD (1984) Neuro-otological manifestations of migraine. Brain 107:1123–1142PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2009

Authors and Affiliations

  1. 1.Dept. of NeurologyJohannes Gutenberg UniversityMainzGermany

Personalised recommendations